Kenya’s healthcare is at a crossroads, time to act now

Kenya's healthcare system exemplifies a critical paradox facing emerging African markets: ambitious technological modernization initiatives colliding with deteriorating foundational infrastructure. As non-communicable diseases (NCDs)—particularly cancer, diabetes, and cardiovascular conditions—surge across East Africa's largest economy, the government's substantial investments in digital health systems have yielded minimal returns, leaving public hospitals chronically underfunded and operationally dysfunctional. The implications for European investors seeking healthcare opportunities in Kenya are profound and multifaceted. While the disease burden is genuinely expanding, driven by urbanization, lifestyle changes, and aging demographics, the public sector's inability to deliver basic services creates both obstacles and unconventional opportunities. Kenya's cancer incidence has risen dramatically over the past decade, with an estimated 45,000 new cases annually—a trajectory mirroring global NCD trends in middle-income countries. Yet public hospitals lack essential oncology infrastructure: chemotherapy stocks remain inconsistent, radiotherapy equipment operates below capacity, and diagnostic capabilities remain severely limited. This treatment gap represents the healthcare system's broader dysfunction. The government has committed billions to electronic health records systems, mobile health applications, and digital payment platforms that remain largely unutilized or poorly integrated. Meanwhile, basic necessities—functioning surgical theaters, reliable pharmaceutical supplies, adequately trained staff—remain critically scarce. For European healthcare investors, this situation presents a complex landscape